Godavari Biorefineries Limited (GODAVARIB) — Announcement

· NSE Neutral
📢 Key Event
Company granted Japanese patent for cancer treatment compound
💡 Investor Takeaway
The patent strengthens Godavari's oncology pipeline and long-term shareholder value.

Godavari Biorefineries announced that Japan's patent office granted a patent for its cancer-treating compound, covering a novel class of molecules effective against breast and prostate cancer. The patent, numbered 7869786, was registered on May 26, 2026, and includes a grant certificate attached to the filing. This intellectual property milestone strengthens the company's oncology pipeline and long-term value potential for shareholders.

📄 View Original Announcement (PDF)

About Godavari Biorefineries Limited (GODAVARIB)

Fast Moving Consumer Goods · Diversified FMCG · Listed on NSE

Market Cap: ₹1,527.86 Cr P/E: 67.7

View full GODAVARIB stock details →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when GODAVARIB files new disclosures

Track GODAVARIB filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GODAVARIB — Free

Free account · No credit card · 2 AI queries/day